Trial NCT04444674, PACTR202006922165132
Publication Madhi S, Lancet, 2021
Primary outcome on the report: Local and systemic reactogenicity and adverse events for 7 and 28 days following vaccination; cellular and humoral immunogenicity of ChAdOx1 nCoV-19, as assessed by quantification of serum antibody (IgG) to SARS-CoV-2 full-length spike (FLS) protein, receptor-binding domain (RBD), and virus neutralizing antibody (NAb) assays against live and/or pseudotyped SARS-CoV-2 virus for 7 days after receipt of vaccine

Note: The risk of bias by domain corresponds to the highest risk of bias among outcomes by domain.
The overall risk of bias corresponds to the overall highest risk of bias assessed among outcomes.